Medications on hospital discharge and postprocedure characteristics of patients after propensity score matching
| Characteristics | PPI users | PPI non-users | P value | Standardised difference |
| N=6738 | N=6738 | |||
| Duration of PPI after PCI, median (IQR)—days | 1314 (718–1901) | 0 (0–0) | <0.001 | −2.580 |
| On PPI >30 days after cessation of P2Y12 inhibitor | 5736 (85.3%) | 0 (0.0%) | <0.001 | −3.411 |
| Aspirin on discharge | 6614 (98.2%) | 6591 (97.8%) | 0.16 | −0.024 |
| P2Y12 inhibitors on discharge | 6722 (99.8%) | 6705 (99.5%) | 0.015 | −0.042 |
| Potent P2Y12 inhibitors on discharge* | 1793 (26.6%) | 659 (9.8%) | <0.001 | −0.447 |
| Duration of P2Y12 inhibitor after PCI (IQR)—days | 366 (365, 425) | 365 (184, 387) | <0.001 | −0.147 |
| Anticoagulation on discharge | 258 (3.8%) | 153 (2.3%) | <0.001 | −0.091 |
| Metformin on discharge | 1483 (22.0%) | 1512 (22.4%) | 0.55 | 0.010 |
| Statin on discharge | 6514 (96.7%) | 6403 (95.0%) | <0.001 | −0.083 |
| Angiotensin blockade on discharge | 4930 (73.2%) | 4680 (69.5%) | <0.001 | −0.082 |
| Beta-blocker on discharge | 4975 (73.8%) | 5166 (76.7%) | <0.001 | 0.066 |
| Drop in haemoglobin >2 g/dL after PCI | 1497 (22.2%) | 1301 (19.3%) | <0.001 | −0.072 |
| Gastrointestinal bleeding during follow-up | 362 (5.4%) | 336 (5.0%) | 0.31 | −0.017 |
| Upper endoscopy during follow-up | 1076 (16.0%) | 957 (14.2%) | 0.004 | −0.049 |
*Potent P2Y12 inhibitors=ticagrelor or prasugrel.
PCI, percutaneous coronary intervention; PPI, proton pump inhibitor.;